Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MC5R | P33032 | 5/20 | 0.46 |
| ▸ | MC3R | P41968 | 5/20 | 0.46 |
| ▸ | MC4R | P32245 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181395 | 0.92 | CCR6 (0.61) | CCR6PAX8MAOAMC5RMC3R | |
| SCHEMBL7535687 | 0.92 | CCR6 (0.64) | CCR6PAX8MAOAMC5RMC3R | |
| SCHEMBL759516 | 0.90 | CCR6 (0.66) | CCR6PAX8MAOAMC5RMC3R | |
| SCHEMBL29875737 | 0.85 | CCR6 (0.56) | CCR6PAX8MAOAMC5RMC3R | |
| SCHEMBL2076709 | 0.84 | CCR6 (0.59) | CCR6PAX8MC5RMC3RMC4R | |
| SCHEMBL15355992 | 0.84 | CCR6 (0.59) | CCR6PAX8TDP1 | |
| SCHEMBL17377997 | 0.83 | CCR6 (0.61) | CCR6PAX8MC5RMC3RMC4R | |
| SCHEMBL5557184 | 0.82 | CCR6 (0.58) | CCR6PAX8LMNAKMT2ATDP1 | |
| SCHEMBL2075425 | 0.82 | CCR6 (0.60) | CCR6PAX8LMNA | |
| SCHEMBL416941 | 0.82 | CCR6 (0.64) | CCR6PAX8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402673-B2 | Diamine β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-02-14 | — | — | US | disclosed |
| EP-1751086-A2 | DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005121065-A2 | DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272769-A1 | Diamine beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272769-A1 | Diamine beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2C | CCR6 1005/4885PAX8 4353/4885MAOA 294/4885 |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2C | CCR6 1005/4885PAX8 4353/4885MAOA 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.